Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
MRVI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $16.95M rose 149.6% year over year, ahead of the -36.2% change in trailing-twelve-month stock-based compensation.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, down 19.1 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +149.6% holds above the trailing-twelve-month pace of -36.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 49.42M | +42.9% |
| FY2023 | 2023-12-31 | 34.59M | +85.3% |
| FY2022 | 2022-12-31 | 18.67M | +78.5% |
| FY2021 | 2021-12-31 | 10.46M | — |
Stock-Based Compensation vs competitors
How MRVI compares with its peers on the latest reported figures
- MRVI's LTM Jun 2026 stock-based compensation of $26M is the 5th largest of the 9 companies compared; the peer median is $25.56M.
- Its year-over-year change of -36.2% is the 6th highest of 9, against a peer median of -22.1%.
- Stock-based compensation amounts to 12.5% of revenue for MRVI, versus a peer median of 3.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $45.8M | +43.1% | -1.6% | 1.8% | |
| LTM Sep 2026 | $43.09M | +56.0% | +1.8% | 3.5% | |
| LTM Jun 2026 | $33.29M | -26.1% | +6.1% | 4.2% | |
| LTM Mar 2026 | $27.48M | -5.7% | +25.8% | 31.9% | |
| LTM Jun 2026 | $26M | -36.2% | — | 12.5% | |
| LTM Mar 2026 | $23.65M | -18.2% | -3.2% | 23.7% | |
| LTM Sep 2026 | $12.24M | -41.4% | +9.3% | 2.0% | |
| LTM Aug 2026 | $11.54M | -36.9% | +9.6% | 1.3% | |
| LTM Mar 2026 | $9.59M | -84.2% | -19.1% | 6.0% | |
| Peer median (excluding MRVI) | $25.56M | -22.1% | +3.9% | 3.9% | |
Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 469.25M | 490.66M | (119.03M) | (259.62M) | (130.77M) |
| Depreciation & Amortization | 24.75M | 38.1M | 48.78M | 56.87M | 60.47M |
| Deferred Income Tax | 46.9M | 42.32M | 754.94M | 2.32M | (20K) |
| Stock-Based Compensation | 10.46M | 18.67M | 34.59M | 49.42M | 0 |
| Change in Working Capital | (176.63M) | (45.08M) | 97.84M | (12.61M) | (7.98M) |
| Accounts Receivables | (70.39M) | (22.27M) | 84.4M | 14.36M | 12.82M |
| Inventory | (21.57M) | 9.46M | 649K | 377K | 8M |
| Accounts Payables | 676K | (1.58M) | 5.28M | 723K | (7.35M) |
| Other Working Capital | (85.34M) | (30.69M) | 7.52M | (28.07M) | (21.45M) |
| Other Non-Cash Items | (6.16M) | (8.7M) | (690.9M) | 171.1M | 20.73M |
| Operating Cash Flow | 368.57M | 535.98M | 126.22M | 7.47M | (57.57M) |
| Capital Expenditures | (14.85M) | (17.09M) | (65.55M) | (29.66M) | (13.15M) |
| Acquisitions (Net) | 119.96M | (238.35M) | (69.62M) | 0 | (18.26M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 548K | (12.17M) | 12.87M | 5.34M | 0 |
| Investing Cash Flow | 105.66M | (267.61M) | (122.31M) | (24.32M) | (31.41M) |
| Debt Repayment | (6M) | (5.44M) | (5.77M) | (234.07M) | (5.44M) |
| Common Stock Issued | 1.71M | 2.36M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | (20K) | (2.08M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (154.76M) | (184.42M) | (55.3M) | 443K | (11.06M) |
| Financing Cash Flow | (159.05M) | (187.5M) | (61.09M) | (235.71M) | (16.5M) |
| Effect of Forex Changes | (88K) | 0 | 0 | 0 | (32K) |
| Net Change in Cash | 315.09M | 80.87M | (57.18M) | (252.56M) | (105.51M) |
| Free Cash Flow | 353.72M | 518.89M | 60.67M | (22.19M) | (70.72M) |
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
Intrinsic Alpha fair value
Locked
Current Price
$7.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.